DURHAM, N.C., March 19, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the company will be presenting at the Second Annual Regen Med Investor Day hosted by the Alliance for Regenerative Medicine on March 26, and the 4th Annual Cancer Immunotherapy: A Long Awaited Reality Conference presented by Maidstone Life Sciences on March 27. Frederick Miesowicz, Ph.D., chief operating officer of Argos, will be presenting on behalf of the company at both events and will be providing an update on progress related to the development of AGS-003, Argos’s fully personalized immunotherapy currently in a pivotal phase 3 clinical trial for the treatment of metastatic renal cell carcinoma, and upcoming milestones.
Help employers find you! Check out all the jobs and post your resume.
